In continuation of the goals of this paper, it is advised that further attention be given to these endpoints and parameters to help researchers and clinicians solidify the comprehensive role of PCSK9 inhibitors in populations with statin intolerance or statin-resistant hyperlipidemia. Here, PCSK9 is linked to hyperlipidemia.